Besides, a variety of ADAM17 substrates including the EGFR-ligands AREG and TGF-α were detected in patient-derived ascites of ovarian cancer patients, suggesting that ADAM17 is highly active in these patients [25]. This evidence concerns the gene AREG and ovarian carcinoma.